{{Rsnum
|rsid=2073524
|Gene=DAXX
|Chromosome=6
|position=33322770
|Orientation=plus
|GMAF=0.4858
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(A;A)
|geno2=(A;T)
|geno3=(T;T)
|Gene_s=DAXX
}}{{ population diversity
| geno1=(A;A)
| geno2=(A;T)
| geno3=(T;T)
| CEU | 23.1 | 47.7 | 29.2
| HCB | 15.6 | 62.2 | 22.2
| JPT | 11.6 | 46.5 | 41.9
| YRI | 28.6 | 52.4 | 19.0
| ASW | 0.0 | 0.0 | 0.0
| CHB | 15.6 | 62.2 | 22.2
| CHD | 0.0 | 0.0 | 0.0
| GIH | 0.0 | 0.0 | 0.0
| LWK | 0.0 | 0.0 | 0.0
| MEX | 0.0 | 0.0 | 0.0
| MKK | 0.0 | 0.0 | 0.0
| TSI | 0.0 | 0.0 | 0.0
| HapMapRevision=28
}}{{PharmGKB
|RSID=rs2073524
|Name_s=intron 1 c.-50+92G>A
|Gene_s=DAXX, ZBTB22, TAPBP
|Feature=
|Evidence=PubMed ID:19837266
|Annotation=Risk or phenotype-associated allele, tested allele: unspecified; minor allele designation varies by ethnicity in dbSNP Phenotype: In 114 cases and 414 controls (n = 528), univariate analysis of disease association showed OR = 0.94 for heterozygote, OR = 0.99 for homozygous, versus homozygous wild type, in ALL, with P(trend) OR = 0.99, p = 0.97 using an additive model. Study size: 528. Study population/ethnicity: Childhood acute lymphoblastic leukemia (<=14 years) and healthy newborn controls (1988 to 1999) from South Wales in the United Kingdom. Significance metric(s): Non-significant finding p = 0.97. Type of association: CO.
|Drugs=
|Drug Classes=
|Diseases=Precursor Cell Lymphoblastic Leukemia-Lymphoma
|Curation Level=Curated
|PharmGKB Accession ID=PA165110224
}}

{{PharmGKB
|RSID=rs2073524
|Name_s=intron 1 c.-50+92G>A
|Gene_s=DAXX, ZBTB22, TAPBP
|Feature=
|Evidence=PubMed ID:19837266
|Annotation=Risk or phenotype-associated allele: combined alleles of TP53 rs1042522 (R72P), and DAXX rs2073524; both alleles unspecified; for both alleles, minor allele designation varies by ethnicity in dbSNP. Phenotype: There was suggestive evidence for interaction between DAXX rs2073524 and TP53 rs1042522 (R72P) alleles in risk of childhood ALL for homozygous genotypes (p = 0.05). Disease risk association with TP53 rs1042522 (R72P) increased in the presence of the DAXX rs2073524 variant allele (OR per allele = 1.49, p = 0.005). This interaction was female-specific (OR per allele = 2.41, p = 0.004), where the risk conferred by TP53 rs1042522 (R72P) homozygosity was greater for girls carrying the wild-type MDM2 genotype (OR = 7.1, p = 0.02). Study size: 528. Study population/ethnicity: 114 cases childhood acute lymphoblastic leukemia (<=14 years) and 414 healthy newborn controls (1988 to 1999) from South Wales in the United Kingdom. Significance metric(s): OR = (1.49 to 7.1), p = (0.004 to 0.05) Type of association: CO
|Drugs=
|Drug Classes=
|Diseases=Precursor Cell Lymphoblastic Leukemia-Lymphoma
|Curation Level=Curated
|PharmGKB Accession ID=PA165110244
}}

{{GET Evidence
|impact=pharmacogenetic
|qualified_impact=Insufficiently evaluated pharmacogenetic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs2073524
|overall_frequency_n=63
|overall_frequency_d=124
|overall_frequency=0.508065
|n_genomes=39
|n_genomes_annotated=0
|n_haplomes=55
|n_articles=1
|n_articles_annotated=0
|in_pharmgkb=Y
|autoscore=1
|webscore=N
}}

{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | HumanOmni1Quad}}